|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yu B and Xie J: Identifying therapeutic
targets in gastric cancer: The current status and future direction.
Acta Biochim Biophys Sin (Shanghai). 48:90–96. 2016.PubMed/NCBI
|
|
4
|
Sakai D, Satoh T, Kurokawa Y, Kudo T,
Nishikawa K, Oka Y, Tsujinaka T, Shimokawa T, Doki Y and Furukawa
H: A phase II trial of trastuzumab combined with irinotecan in
patients with advanced HER2-positive chemo-refractory gastric
cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group
OGSG1203 (HERBIS-5). Jpn J Clin Oncol. 43:838–840. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gumusay O, Benekli M, Ekinci O, Baykara M,
Ozet A, Coskun U, Demirci U, Uner A, Dursun A, Atak EY, et al:
Discordances in HER2 status between primary gastric cancer and
corresponding metastatic sites. Jpn J Clin Oncol. 45:416–421. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: ToGA Trial Investigators: Trastuzumab in combination with
chemotherapy versus chemotherapy alone for treatment of
HER2-positive advanced gastric or gastro-oesophageal junction
cancer (ToGA): A phase 3, open-label, randomised controlled trial.
Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Corrigan PA, Cicci TA, Auten JJ and Lowe
DK: Ado-trastuzumab emtansine: A HER2-positive targeted
antibody-drug conjugate. Ann Pharmacother. 48:1484–1493. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ahn ER, Wang E and Glück S: Is the
improved efficacy of trastuzumab and lapatinib combination worth
the added toxicity? A discussion of current evidence,
recommendations, and ethical issues regarding dual HER2-targeted
therapy. Breast Cancer (Auckl). 6:191–207. 2012.PubMed/NCBI
|
|
9
|
Moghaddas A and Borhani A: Whether
HER2-positive non-breast cancers are candidates for treatment with
Ado-trastuzumab emtansine? J Res Pharm Pract. 5:227–233. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Barok M, Tanner M, Köninki K and Isola J:
Trastuzumab-DM1 is highly effective in preclinical models of
HER2-positive gastric cancer. Cancer Lett. 306:171–179. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yamashita-Kashima Y, Shu S, Harada N and
Fujimoto-Ouchi K: Enhanced antitumor activity of trastuzumab
emtansine (T-DM1) in combination with pertuzumab in a HER2-positive
gastric cancer model. Oncol Rep. 30:1087–1093. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shitara K and Ohtsu A: Advances in
systemic therapy for metastatic or advanced gastric cancer. J Natl
Compr Canc Netw. 14:1313–1320. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gupta N, Hatoum H and Dy GK: First line
treatment of advanced non-small-cell lung cancer - specific focus
on albumin bound paclitaxel. Int J Nanomed. 9:209–221. 2014.
|
|
14
|
Yamamoto T, Miyazaki T, Kurashima Y, Ohata
K, Okawa M, Tanaka S, Uenishi T and Ohno K: A case report of
successful chemotherapy with tegafur/gimeracil/oteracil and
nab-paclitaxel for gastric cancer with chronic renal failure. Gan
To Kagaku Ryoho. 42:735–738. 2015.(In Japanese). PubMed/NCBI
|
|
15
|
Vogel A, Kullmann F, Kunzmann V, Al-Batran
SE, Oettle H, Plentz R, Siveke J, Springfeld C and Riess H:
Patients with advanced pancreatic cancer and hyperbilirubinaemia:
Review and German expert opinion on treatment with nab-paclitaxel
plus Gemcitabine. Oncol Res Treat. 38:596–603. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hirsh V: nab-paclitaxel for the management
of patients with advanced non-small-cell lung cancer. Expert Rev
Anticancer Ther. 14:129–141. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Montero AJ, Adams B, Diaz-Montero CM and
Glück S: nab-paclitaxel in the treatment of metastatic breast
cancer: A comprehensive review. Expert Rev Clin Pharmacol.
4:329–334. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ruttala HB, Ramasamy T, Shin BS, Choi HG,
Yong CS and Kim JO: Layer-by-layer assembly of hierarchical
nanoarchitectures to enhance the systemic performance of
nanoparticle albumin-bound paclitaxel. Int J Pharm. 519:11–21.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
van Lith SA, van Duijnhoven SM, Navis AC,
Leenders WP, Dolk E, Wennink JW, van Nostrum CF and van Hest JC:
Legomedicine - A versatile chemo-enzymatic approach for the
preparation of targeted dual-labeled llama antibody-nanoparticle
conjugates. Bioconjug Chem. 28:539–548. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Obaid G, Chambrier I, Cook MJ and Russell
DA: Cancer targeting with biomolecules: A comparative study of
photodynamic therapy efficacy using antibody or lectin conjugated
phthalocyanine-PEG gold nanoparticles. Photochem Photobiol Sci.
14:737–747. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen L, Chen F, Zhao M, Zhu X, Ke C, Yu J,
Yan Z, Zhang F, Sun Y, Chen D, et al: A redox-sensitive
micelle-like nanoparticle self-assembled from amphiphilic
adriamycin-human serum albumin conjugates for tumor targeted
therapy. Biomed Res Int. 2015:9874042015.PubMed/NCBI
|
|
23
|
Su LY, Shi YX, Yan MR, Xi Y and Su XL:
Anticancer bioactive peptides suppress human colorectal tumor cell
growth and induce apoptosis via modulating the PARP-p53-Mcl-1
signaling pathway. Acta Pharmacol Sin. 36:1514–1519. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Moon JY, Cho M, Ahn KS and Cho SK:
Nobiletin induces apoptosis and potentiates the effects of the
anticancer drug 5-fluorouracil in p53-mutated SNU-16 human gastric
cancer cells. Nutr Cancer. 65:286–295. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Korbakis D and Scorilas A: Quantitative
expression analysis of the apoptosis-related genes BCL2, BAX and
BCL2L12 in gastric adenocarcinoma cells following treatment with
the anticancer drugs cisplatin, etoposide and taxol. Tumour Biol.
33:865–875. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lindsay J, Esposti MD and Gilmore AP:
Bcl-2 proteins and mitochondria - specificity in membrane targeting
for death. Biochim Biophys Acta. 1813:532–539. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gonzalez-Campora R, Davalos-Casanova G,
Beato-Moreno A, Garcia-Escudero A, Pareja Megia MJ, Montironi R and
Lopez-Beltran A: BCL-2, TP53 and BAX protein expression in
superficial urothelial bladder carcinoma. Cancer Lett. 250:292–299.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sriramoju B, Kanwar RK and Kanwar JR:
Nanoformulated cell-penetrating survivin mutant and its dual
actions. Int J Nanomed. 9:3279–3298. 2014.
|
|
29
|
Altieri DC: Survivin, cancer networks and
pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Toiyama Y, Tanaka K, Konishi N, Mohri Y,
Tonouchi H, Miki C and Kusunoki M: Administration
sequence-dependent antitumor effects of paclitaxel and
5-fluorouracil in the human gastric cancer cell line MKN45. Cancer
Chemother Pharmacol. 57:368–375. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Matsuhashi N, Saio M, Matsuo A, Sugiyama Y
and Saji S: Apoptosis induced by 5-fluorouracil, cisplatin and
paclitaxel are associated with p53 gene status in gastric cancer
cell lines. Int J Oncol. 26:1563–1567. 2005.PubMed/NCBI
|
|
32
|
Arranja A, Gouveia LF, Gener P, Rafael DF,
Pereira C, Schwartz S Jr and Videira MA: Self-assembly PEGylation
assists SLN-paclitaxel delivery inducing cancer cell apoptosis upon
internalization. Int J Pharm. 501:180–189. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bender B, Leipold DD, Xu K, Shen BQ,
Tibbitts J and Friberg LE: A mechanistic pharmacokinetic model
elucidating the disposition of trastuzumab emtansine (T-DM1), an
antibody-drug conjugate (ADC) for treatment of metastatic breast
cancer. AAPS J. 16:994–1008. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Krop IE, Lin NU, Blackwell K, Guardino E,
Huober J, Lu M, Miles D, Samant M, Welslau M and Diéras V:
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in
patients with HER2-positive metastatic breast cancer and central
nervous system metastases: A retrospective, exploratory analysis in
EMILIA. Ann Oncol. 26:113–119. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Elzoghby AO, Samy WM and Elgindy NA:
Protein-based nanocarriers as promising drug and gene delivery
systems. J Control Release. 161:38–49. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ruan J, Ji J, Song H, Qian Q, Wang K, Wang
C and Cui D: Fluorescent magnetic nanoparticle-labeled mesenchymal
stem cells for targeted imaging and hyperthermia therapy of in vivo
gastric cancer. Nanoscale Res Lett. 7:3092012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Regino CAS, Ogawa M, Alford R, Wong KJ,
Kosaka N, Williams M, Feild BJ, Takahashi M, Choyke PL and
Kobayashi H: Two-step synthesis of galactosylated human serum
albumin as a targeted optical imaging agent for peritoneal
carcinomatosis. J Med Chem. 53:1579–1586. 2010. View Article : Google Scholar : PubMed/NCBI
|
